Oracle Corporation

New York Stock Exchange
Back to all articles
Bullish +55

Fund Update: 422,508 ORACLE (ORCL) shares added to CANTILLON CAPITAL MANAGEMENT LLC portfolio - Quiver Quantitative

📈 Cantillon Capital Management added 422,508 shares of ORCL to its portfolio per a Q1 2026 SEC 13F filing.

📉 UBS Asset Management removed $6.99 billion worth of shares (-72.7%), while Capital Research Global Investors added $1.33 billion (+29.3%).

💰 Oracle insiders sold stock six times in the last six months, including CEO Clayton Magouyerk selling 20,000 shares.

🏛️ Members of Congress traded ORCL eight times recently, with Representative Jared Moskowitz making three sales totaling up to $80,000.

💵 The company received $1.299 billion in award payments over the last year, including major EHRM and government contract deployments.

📊 Seven Wall Street firms issued buy or overweight ratings on ORCL recently, with zero sell ratings recorded.

🎯 Analyst price targets range from $200 to $400, with a median target of $227.0 set by 28 analysts.

📅 Specific analyst targets include John Difucci at Guggenheim ($400) and Siti Panigrahi at Mizuho ($320).

Bullish Signals
  • Cantillon Capital Management increased its position in ORCL, signaling continued institutional interest despite broader sector rotation.
  • Capital Research Global Investors significantly added $1.33 billion to their ORCL holdings, representing a 29.3% increase in their position.
  • BlackRock and Vanguard both increased their stakes, with BlackRock adding over $1.58 billion and Vanguard adding $1.14 billion.
  • Wall Street consensus is bullish, with seven firms issuing buy or overweight ratings and zero firms issuing sell ratings recently.
  • Analyst price targets show strong upside potential, with the highest target of $400 from Guggenheim exceeding the median of $227.
Risk Factors
  • Oracle insiders have been net sellers over the past six months, with zero purchases and six sales totaling significant value.
  • UBS Asset Management drastically reduced its position by removing $6.99 billion worth of shares, a move of -72.7%.
  • Arrowstreet Capital completely exited its position (-100.0%), removing $906 million from its portfolio.
  • Capital World Investors significantly decreased their holdings by removing $1.02 billion (-76.7%) from their portfolio.
Full Analysis
Cantillon Capital Management LLC added 422,508 shares of Oracle (ORCL) to its portfolio based on a Q1 2026 SEC 13F filing. This update highlights broader institutional activity where 1,611 investors increased their positions while 2,096 decreased them in the most recent quarter. Notable moves include UBS Asset Management removing over $6.9 billion worth of shares and Capital Research Global Investors adding $1.33 billion. Oracle insiders have been net sellers over the past six months, with CEO Clayton Magouyerk selling 20,000 shares and other executives like EVP Douglas Kehring offloading significant holdings. Additionally, members of Congress have traded the stock eight times recently, with Representative Jared Moskowitz making three sales. The company also saw $1.299 billion in award payments over the last year, including major deployments for EHRM waves and operational management services contracts. Wall Street sentiment remains bullish with seven firms issuing buy or overweight ratings on ORCL in recent months. Analyst price targets vary widely, ranging from Brad Sills' $200 target at B of A Securities to John Difucci's $400 target at Guggenheim. The median price target among 28 analysts is set at $227.0, with specific targets provided by Wedbush, Morgan Stanley, and Mizuho. The article concludes with unrelated market news regarding Elizabeth Warren's comments on the SpaceX IPO, a merger update for Trump Media and TAE Technologies, and inflation data showing May figures hitting 4.2% due to energy prices.